Korea-based Peptron published data showing positive results from preclinical tests of their sustained-release version of exenatide—a peptide that can cross the blood brain barrier and potentially protect the brain in Parkinson’s disease.
“The peer-review and publication of this data is an important step in confirming the ability of our novel SR-exenatide drug to cross the blood-brain barrier and deliver long-acting therapeutic effects of the neuroprotective peptide,” said Peptron’s CEO Ho-Il Choi, Ph.D., in a statement.
Read more:
FierceBiotech: Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease